Abstract:OBJECTIVES: This study evaluated the efficacy and safety of a novel asthma management strategy--budesonide/formoterol for both maintenance and symptom relief (Symbicort Single Inhaler Therapy)--compared with a higher maintenance dose of budesonide in patients with moderate to severe asthma.METHODS: This was a 12-month, randomised, double-blind, parallel-group study. Symptomatic patients with asthma (n = 1890; mean age 43 years [range 11 years-80 years], mean baseline forced expiratory volume in 1 s [FEV(1)] 70% of predicted, mean inhaled corticosteroid [ICS] dose 746 microg/day) received either budesonide (160 microg, 2 inhalations twice daily) plus terbutaline 0.4 mg as needed or a daily maintenance dose of budesonide/formoterol (160/4.5 microg, 2 inhalations once daily) with additional inhalations of budesonide/formoterol 160/4.5 microg as needed. Time to first severe exacerbation (hospitalisation/emergency room [ER] treatment or systemic steroids due to asthma worsening or a fall in morning peak expiratory flow [PEF] to < or = 70% of baseline on 2 consecutive days) was the primary outcome variable.RESULTS: A total of 1890 patients were randomised, of whom 1563 (83%) had severe asthma. The time to first severe exacerbation was prolonged by budesonide/formoterol single inhaler therapy (p < 0.001) compared with a higher dose of budesonide. The risk of having a severe exacerbation was 39% lower with budesonide/formoterol single inhaler therapy compared with budesonide (p < 0.001). The number needed to treat to prevent one severe exacerbation per year with budesonide/formoterol compared with budesonide was 5. The budesonide/formoterol group had 45% fewer severe exacerbations requiring medical intervention per patient compared with the budesonide group (p < 0.001). Budesonide/formoterol patients had fewer hospitalisations/ER treatments (15 vs 25 events, respectively [descriptive statistics]) and fewer treatment days with systemic steroids (1776 days vs 3177 days, respectively [descriptive statistics]) compared with budesonide patients. Budesonide/formoterol single inhaler therapy patients used less as-needed medication compared with budesonide patients (0.90 vs 1.42 inhalations/day; p < 0.001). The mean daily ICS dose was lower in the budesonide/formoterol group than in the budesonide group (466 microg/day vs 640 microg/day). Over the 12-month study period, the budesonide/formoterol group achieved asthma control sufficient to not require any additional as-needed medication on 60% of days. Overall, budesonide/formoterol single inhaler therapy gave 31 more asthma control days (a night and day with no asthma symptoms and no as-needed medication use) per patient-year and 12 additional undisturbed nights per patient-year compared with a higher dose of budesonide. Both treatments were well tolerated.CONCLUSION: Budesonide/formoterol single inhaler therapy has the potential to provide a complete asthma management approach with one inhaler, demonstrating a high level of efficacy in patients with moderate to severe asthma.

Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis

Treatment of Pediatric Mild Persistent Asthma with Low-Dose Budesonide Inhalation Suspension Vs.montelukast in China

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

Inhaled Budesonide vis-à-vis Inhaled Mometasone in Chinese Children with Mild Persistent Asthma: A Single-Center, Retrospective Study

Budesonide/Formoterol Maintenance and Reliever Therapy in Chinese Patients with Asthma

Treatment of pediatric mild persistent asthma with low-dose budesonide inhalation suspension vs. montelukast in China

A Three-Month Non-Interventional Study of Asthma Treatment with Budesonide/Formoterol

Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis

[Evaluation of the Clinical Efficacy and the Safety of Salmeterol/fluticasone Propionate Accuhaler Compared to Budesonide Turbuhalar in the Control of Adult Asthma].

The Cost-Effectiveness of Low-Dose Budesonide As a Step 2 Treatment for Pediatric Asthma in China

A Meta-analysis of salmeterol fluticasone combined with montelukast in the treatment of asthma in children

Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study.

Budesonide in Combination with Salbutamol in the Treatment of 61 Cases of Childhood Bronchial Asthma During Acute Episodes

Cost-effectiveness Analysis of Double Low-Dose Budesonide and Low-Dose Budesonide Plus Montelukast among Pediatric Patients with Persistent Asthma Receiving Step 3 Treatment in China

Efficacy and Safety of Budesonide/formoterol Single Inhaler Therapy Versus Budesonide Inhaler Plus Formoterol Inhaler in Asthma Patients

Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial

Budesonide and Formoterol in a Single Inhaler Improves Asthma Control Compared With Increasing the Dose of Corticosteroid in Adults With Mild-to-Moderate Asthma

Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis

The Efficacy of Budesonide-formoterol in Patients with Acute Attacks of Mild-to-moderate Bronchial Asthma: An Observational Study